Peripheral T-cell Lymphoma

P1/2, N=254, Recruiting, Haihe Biopharma Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027

The patient was treated with a modified MARIETTA protocol (without rituximab) and consolidated with a carmustine-based autologous stem cell transplant. shows complete metabolic response on PET-CT and MRI brain. This case presents the first successful treatment of a synchronous presentation of CNS and systemic ALK-positive ALCL, and the importance of a multidisciplinary approach for diagnosis.

P2, N=26, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University

P1/2, N=43, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P1, N=26, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Dec 2025

The patient achieved complete remission with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy and remains disease-free after three years. To our knowledge, this represents the first reported case of primary bilateral subconjunctival PTCL-NOS successfully managed with systemic chemotherapy, highlighting the importance of comprehensive evaluation and aggressive treatment in this unusual presentation.

This case represents a rare pcTFH-PTCL with a persistent T-cell clone coexisting with divergent clonal B- and plasma cell populations. The findings emphasize the role of TFH-derived neoplasms in fostering B-cell expansions and highlight the diagnostic and therapeutic complexity posed by dual-lineage clonality in cutaneous lymphomas.

P2, N=26, Recruiting, The First Affiliated Hospital of Soochow University

P2, N=44, Not yet recruiting, Boryung Pharmaceutical Co., Ltd | Initiation date: Sep 2025 --> Feb 2026

CHOP or CHOP-like regimens have long been the standard frontline therapy; however, the addition of brentuximab vedotin has improved overall survival and established a new standard of care for CD30-positive PTCL...Epigenetic modulators, including histone deacetylase inhibitors and an EZH1/2 inhibitor, have demonstrated particularly high activity in TFH-derived subtypes, supporting the integration of biomarker-driven patient selection as a path toward precision medicine in PTCL. This review summarizes current insights into the genetic landscape, recent clinical advances in novel agents, and future perspectives on therapeutic stratification, highlighting the need to translate molecular insights into durable clinical benefits for patients with PTCL.

P1, N=22, Terminated, Seagen, a wholly owned subsidiary of Pfizer | Completed --> Terminated; Study terminated as part of strategic considerations

Chidamide combined with ENO1 knockdown enhanced the effect of the inhibitor on promoting apoptosis and cell cycle arrest in PTCL-NOS tumor cells. Taken together, the findings suggest that knockdown of ENO1 activates autophagy and promotes ferroptosis, thereby inhibiting PTCL-NOS cell proliferation.